Zacks Small Cap Comments on CEL-SCI Co.’s FY2024 Earnings (NYSE:CVM)

CEL-SCI Co. (NYSE:CVM) – Investment analysts at Zacks Small Cap cut their FY2024 EPS estimates for shares of CEL-SCI in a research report issued on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will earn ($0.51) per share for the year, down from their prior estimate of ($0.48). The consensus estimate for CEL-SCI’s current full-year earnings is ($0.51) per share.

CEL-SCI (NYSE:CVM) last announced its quarterly earnings results on Wednesday, February 14th. The company reported ($0.14) EPS for the quarter.

Separately, StockNews.com cut shares of CEL-SCI from a “hold” rating to a “sell” rating in a research report on Friday, March 15th.

CEL-SCI Stock Performance

NYSE CVM opened at $1.52 on Wednesday. CEL-SCI has a 1 year low of $1.04 and a 1 year high of $3.23. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.26 and a quick ratio of 0.78. The stock has a market capitalization of $82.05 million, a PE ratio of -2.24 and a beta of 1.29. The company’s 50 day simple moving average is $2.00 and its two-hundred day simple moving average is $2.17.

Hedge Funds Weigh In On CEL-SCI

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of CEL-SCI by 9.4% during the 4th quarter. Vanguard Group Inc. now owns 2,079,624 shares of the company’s stock valued at $5,657,000 after purchasing an additional 178,478 shares during the last quarter. Forthright Family Wealth Advisory LLC bought a new position in shares of CEL-SCI during the 4th quarter valued at $45,000. Virtu Financial LLC bought a new stake in CEL-SCI in the 4th quarter worth $163,000. Cantor Fitzgerald L. P. bought a new stake in CEL-SCI in the 4th quarter worth $329,000. Finally, Northern Trust Corp grew its holdings in CEL-SCI by 7.2% in the 4th quarter. Northern Trust Corp now owns 83,864 shares of the company’s stock worth $228,000 after acquiring an additional 5,629 shares during the last quarter. Institutional investors own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.